-
Oral Oncology Dec 2012Human Papillomavirus (HPV) related oropharyngeal squamous cell carcinomas (OPSCCs) are reported to have improved prognosis and survival in comparison to other head and... (Meta-Analysis)
Meta-Analysis Review
Human Papillomavirus (HPV) related oropharyngeal squamous cell carcinomas (OPSCCs) are reported to have improved prognosis and survival in comparison to other head and neck squamous cell cancers (HNSCCs). This systematic review and meta-analysis examines survival differences in HPV-positive HNSCC and OPSCC subtypes including tonsillar carcinoma in studies not previously investigated. Four electronic databases were searched from their inception till April 2011. A random effects meta-analysis was used to pool study estimates evaluating disease-specific (death from HNSCC), overall (all-cause mortality), progression-free and disease-free (recurrence free) survival outcomes in HPV-positive vs. HPV-negative HNSCCs. All statistical tests were two-sided. Forty-two studies were included. Patients with HPV-positive HNSCC had a 54% better overall survival compared to HPV-negative patients HR 0.46 (95% CI 0.37-0.57); the pooled HR for tonsillar cancer and OPSCC was 0.50 (95% CI 0.33-0.77) and HR 0.47 (95% CI 0.35-0.62) respectively. The pooled HR for disease specific survival was 0.28 (95% CI 0.19-0.40); similar effect sizes were found irrespective of the adjustment for confounders, HPV detection methods or study location. Both progression-free survival and disease-free survival were significantly improved in HPV-positive HNSCCs. HPV-positive HNSCCs and OPSCCs patients have a significantly lower disease specific mortality and are less likely to experience progression or recurrence of their cancer than HPV-negative patients; findings which have connotations for treatment selection in these patients.
Topics: Head and Neck Neoplasms; Humans; Papillomaviridae; Survival Analysis
PubMed: 22841677
DOI: 10.1016/j.oraloncology.2012.06.019 -
The Journal of Infectious Diseases Aug 2021Although human papillomavirus (HPV) vaccines are highly efficacious in protecting against HPV infections and related diseases, vaccination may trigger replacement by...
BACKGROUND
Although human papillomavirus (HPV) vaccines are highly efficacious in protecting against HPV infections and related diseases, vaccination may trigger replacement by nontargeted genotypes if these compete with the vaccine-targeted types. HPV genotype replacement has been deemed unlikely, based on the lack of systematic increases in the prevalence of nonvaccine-type (NVT) infection in the first decade after vaccination, and on the presence of cross-protection for some NVTs.
METHODS
To investigate whether type replacement can be inferred from early postvaccination surveillance, we constructed a transmission model in which a vaccine type and an NVT compete through infection-induced cross-immunity. We simulated scenarios of different levels of cross-immunity and vaccine-induced cross-protection to the NVT. We validated whether commonly used measures correctly indicate type replacement in the long run.
RESULTS
Type replacement is a trade-off between cross-immunity and cross-protection; cross-immunity leads to type replacement unless cross-protection is strong enough. With weak cross-protection, NVT prevalence may initially decrease before rebounding into type replacement, exhibiting a honeymoon period. Importantly, vaccine effectiveness for NVTs is inadequate for indicating type replacement.
CONCLUSIONS
Although postvaccination surveillance thus far is reassuring, it is still too early to preclude type replacement. Monitoring of NVTs remains pivotal in gauging population-level impacts of HPV vaccination.
Topics: Alphapapillomavirus; Genotype; Humans; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Vaccine Efficacy
PubMed: 31985011
DOI: 10.1093/infdis/jiaa032 -
Se Pu = Chinese Journal of... Oct 2020Human papillomavirus (HPV), is a common spherical DNA virus that can lead to six types of cancers later in life, which has recently garnered human's attention. Microchip... (Review)
Review
Human papillomavirus (HPV), is a common spherical DNA virus that can lead to six types of cancers later in life, which has recently garnered human's attention. Microchip capillary electrophoresis (MCE) has provided simple, fast, portable, and sensitive HPV typing assay assisted by a variety of signal amplification technologies. This review presents the latest research progress of MCE in routine HPV typing assays, including both of the MCE techniques and MCE combined with the nucleic acid amplification techniques for HPV assay. The introduction on the former part concerns the MCE system, the MCE chips design and electrophoretic separation methods. The typical MCE system includes high voltage power supply, microfluidic chip of separation, sample injection, electrolyte cell, detection unit and so on. Four different chips are reviewed, containing straight separation channel, T-channel, serpentine channel and dual channel, because these microchips are the most used in the last decade. Furthermore, the high integration and high throughput on a single chip are often integrated the sample preparation unit on a chip. The advantages and disadvantages of different designed microchips are introduced at the same time. The separation methods of chip electrophoresis are briefly introduced. With the development and application of MCE for HPV detection, the separation time is greatly shortened from a few hours to several minutes. The review on the second part gives the comments on various kinds of nucleic acid amplification technologies coupled with MCE for HPV assay. Firstly, the comparative analysis is given on the polymerase chain reaction (PCR) combined with MCE, loop-mediated isothermal amplification (LAMP), PCR combined with restriction fragment length polymorphism (RFLP) for HPV DNA detection, and nucleic acid sequence based amplification (NASBA) for the detection of HPV mRNA, nested PCR and so on. Secondly, the reviews on the other methods beside MCE are also summarized, including the PCR coupled with Fourier transform-infrared spectroscopy (FT-IR spectroscopy), nanotechnology, DNA probes combined with electrochemical methods, reductive Cu(Ⅰ) particles catalyzed Zn-doped MoS quantum dots and T7 exonuclease with electrochemiluminescence, LAMP with CRISPR/Cas12a based lateral. In these non-MCE methods, the electrochemical sensing, e. g., impedimetric detection, pulse voltammetry method and flow biosensor, is an ideal method due to its low background signal and excellent time control ability. Finally, although MCE technologies have been developed and the developed instruments are applied in recent years, there are still some challenges in MCE techniques, methods and applications. The first challenge faced in the application of MCE technique in HPV typing assay is that the MCE device can not be well utilized for the detection of HPV with high resolution and high sensitivity, because MCE can not do signal amplification of HPV nucleic acid. The second challenge is that even though some researchers have successfully integrated PCR and MCE on one chip, the technique still faces difficulty for wide application and there is still no really integrated PCR-MCE chip for HPV detection. The third one is the MCE technique is lack for the manufacture of miniaturized and automatic instrument. At the end of review, the authors' insights are given on the development of automatic, fast, high stable and reliable detection in the HPV typing via the portable MCE device.
Topics: Electrophoresis, Microchip; Humans; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Papillomaviridae; Spectroscopy, Fourier Transform Infrared
PubMed: 34213114
DOI: 10.3724/SP.J.1123.2020.05016 -
Viruses Apr 2024Human papillomavirus (HPV), an oncogenic DNA virus, is the most common sexually transmitted virus and significant public health concern globally. Despite the substantial... (Review)
Review
Human papillomavirus (HPV), an oncogenic DNA virus, is the most common sexually transmitted virus and significant public health concern globally. Despite the substantial prevalence of HPV infection among men, routine testing remains elusive due to the lack of approved HPV tests and the complexity of detection methods. Various studies have explored the link between HPV and genitourinary cancers, revealing different associations influenced by geographic variation, histological subtype and methodological differences. These findings underscore the importance of further research to elucidate the role of HPV in male urogenital cancers. This comprehensive review delves into the intricate relationship between HPV and male genitourinary cancers, shedding light on the virus's oncogenic mechanisms and its reported prevalence. A deeper understanding of HPV's implications for male health is essential for advancing public health initiatives and reducing the burden of urogenital cancers worldwide.
Topics: Humans; Papillomavirus Infections; Male; Carcinogenesis; Urogenital Neoplasms; Papillomaviridae; Prevalence; Human Papillomavirus Viruses
PubMed: 38793549
DOI: 10.3390/v16050667 -
Biomedicine & Pharmacotherapy =... 1997Human papillomavirus (HPV) deoxyribonucleic acid (DNA) has been originally detected in urothelial carcinomas of the bladder in immunocompromized patients. Studies from... (Review)
Review
Human papillomavirus (HPV) deoxyribonucleic acid (DNA) has been originally detected in urothelial carcinomas of the bladder in immunocompromized patients. Studies from the general population showed a variable incidence of high risk HPV DNA which ranged from 2.5% to 81%, with HPV 16 DNA occurring more frequently. HPV DNA was detected in both papillary and invasive cancers, although in our experience the overall incidence was low. Most HPV positive cases were of high grade and stage with significant reduced survival or increased recurrence rate after transurethral resection. These results indicate an additional prognostic value of viral infection in bladder cancer. In addition, molecular studies suggest that the HPV related oncoproteins E6 and E7 play a role in bladder carcinogenesis via inactivation and/or degradation of p53 and pRb suppressor gene-associated proteins. The purpose of this review is to provide a brief summary of what is known about HPV and bladder cancer, and to address issues germane to the translation of this information to patient management.
Topics: DNA, Viral; Humans; Papillomaviridae; Urinary Bladder Neoplasms; Urothelium
PubMed: 9309245
DOI: 10.1016/s0753-3322(97)83540-8 -
Frontiers in Bioscience : a Journal and... May 2008The DNA binding domain of the E2 master regulator from papillomaviruses is the primary effector for most the essential activities controlled by this protein. In this... (Review)
Review
The DNA binding domain of the E2 master regulator from papillomaviruses is the primary effector for most the essential activities controlled by this protein. In this review we focus on the properties of the DNA binding domain of human papillomavirus strain 16 in solution, integrating structure, dynamics, folding, stability, conformational equilibria, and DNA binding mechanism. We discuss the relevance of these processes for the different biological activities, broadening the horizon for antiviral development. In addition, the particular fold of the DNA binding domain only shared with the Epstein-Barr nuclear antigen EBNA1, suggests a link between this unique architecture and the function of viral origin binding proteins of this kind. Finally, the E2 DNA binding domain proved to be an excellent model for addressing fundamental problems of DNA recognition mechanisms and folding of intertwined dimers.
Topics: Alphapapillomavirus; Binding Sites; DNA-Binding Proteins; Humans; Mutation; Papillomaviridae; Transcription Factors; Viral Proteins
PubMed: 18508638
DOI: 10.2741/3132 -
Current Pharmaceutical Design 2014Intrinsically disordered proteins (IDPs) and proteins with long intrinsically disordered protein regions (IDPRs) lack ordered structure but are involved in a multitude... (Review)
Review
Intrinsically disordered proteins (IDPs) and proteins with long intrinsically disordered protein regions (IDPRs) lack ordered structure but are involved in a multitude of biological processes, where they often serve as major regulators and controllers of various functions of their binding partners. Furthermore, IDPs/IDPRs are often related to the pathogenesis of various diseases, including cancer. Intrinsic disorder confers multiple functional advantages to its carriers. As a result, due to their functional versatility and structural plasticity, IDPs and IDPRs are common in various proteomes, including proteomes of different pathological organisms. Viruses are "well-educated" users of various aspects of intrinsic disorder for their advantage. These small but highly efficient invaders broadly use intrinsic disorder to overrun the host organism's defense system, as well as to seize and overrun host systems and pathways forcing them to work for the virus needs, to ensure accommodation of viruses to their variable and often hostile habitats, and to promote and support the economic usage of the viral genetic material. Human papillomaviruses (HPVs), with their tiny proteomes (the entire HPV genome includes just eight open reading frames), intricate life cycle, and ability to either cause benign papillomas/warts or promote the development of carcinomas of the genital tract, head and neck and epidermis, attracted considerable attention of researchers. This review analyzes the plentitude and demeanor of intrinsic disorder in proteins from HPVs and their cellular targets.
Topics: Cell Cycle; Genome, Viral; Humans; Intrinsically Disordered Proteins; Models, Molecular; Oncogene Proteins, Viral; Papillomaviridae; Papillomavirus Infections; Protein Binding; Protein Conformation; Protein Folding
PubMed: 23713779
DOI: 10.2174/13816128113199990072 -
Viruses Aug 2021Human papillomavirus type 159 (HPV159) was identified in an anal swab sample and preliminarily genetically characterized by our group in 2012. Here we present a detailed...
Human papillomavirus type 159 (HPV159) was identified in an anal swab sample and preliminarily genetically characterized by our group in 2012. Here we present a detailed molecular in silico analysis that showed that the HPV159 viral genome is 7443 bp in length and divided into five early and two late genes, with conserved functional domains and motifs, and a non-coding long control region (LCR) with significant regulatory sequences that allow the virus to complete its life cycle and infect novel host cells. HPV159, clustering into the cutaneotropic (-PV) genus, is phylogenetically most similar to HPV9, forming an individual phylogenetic group in the viral species -2. After testing a large representative collection of clinical samples with HPV159 type-specific RT-PCR, in addition to the anal canal from which the first HPV159 isolate was obtained, HPV159 was further detected in other muco-cutaneous (4/181, 2.2%), mucosal (22/764, 2.9%), and cutaneous (14/554, 2.5%) clinical samples, suggesting its extensive tissue tropism. However, because very low HPV159 viral loads were estimated in the majority of positive samples, it seemed that HPV159 mainly caused clinically insignificant infections of the skin and mucosa. Using newly developed, highly sensitive HPV159-specific nested PCRs, two additional HPV159 LCR viral variants were identified. Nevertheless, all HPV159 mutations were demonstrated outside important functional domains of the LCR, suggesting that the HPV159 viral variants were most probably not pathogenically different. This complete molecular characterization of HPV159 enhances our knowledge of the genome characteristics, tissue tropism, and phylogenetic diversity of -PVs that infect humans.
Topics: Genome, Viral; Humans; Papillomaviridae; Papillomavirus Infections; Phylogeny; Viral Load; Viral Proteins
PubMed: 34452532
DOI: 10.3390/v13081668 -
Epidemiology and Infection Aug 2014A series of observational studies were evaluated concerning the risk of human papillomavirus (HPV) infection in pregnancy; however, the results were controversial. We... (Meta-Analysis)
Meta-Analysis Review
A series of observational studies were evaluated concerning the risk of human papillomavirus (HPV) infection in pregnancy; however, the results were controversial. We systematically reviewed and collected data on studies regarding HPV prevalence published up to 30 April 2013, in which HPV was detected in pregnant women or both in pregnant and non-pregnant women. In total, 28 eligible studies were included that provided data on HPV infection concerning 13 640 pregnant women. The overall HPV prevalence in pregnant and age-matched non-pregnant women was 16·82% [95% confidence interval (CI) 16·21-17·47] and 12·25% (95% CI 11·50-13·01), respectively. The prevalence in the in three trimesters was 18·20%, 14·38%, and 19·32%, respectively. HPV-16 was the most frequently observed type, with a prevalence of 3·86% (95% CI 3·40-4·32). The overall HPV prevalence varied by study region, age, and HPV type. The meta-analysis showed a significantly increased risk of HPV infection in pregnant women, with a summary odds ratio (OR) of 1·42 (95% CI 1·25-1·61), especially for those aged <25 years (OR 1·79, 95% CI 1·22-2·63). The results suggest that pregnant women, especially those aged <25 years, are more susceptible to HPV infection.
Topics: Female; Genotype; Humans; Papillomaviridae; Papillomavirus Infections; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Risk Assessment
PubMed: 24667102
DOI: 10.1017/S0950268814000636 -
Journal of Medical Virology Jun 2024Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high-risk human papillomavirus (HR HPV), notably HPV16 and... (Review)
Review
Head and neck cancers (HNCs), primarily head and neck squamous cell carcinoma (HNSCC), are associated with high-risk human papillomavirus (HR HPV), notably HPV16 and HPV18. HPV status guides treatment and predicts outcomes, with distinct molecular pathways in HPV-driven HNSCC influencing survival rates. HNC incidence is rising globally, with regional variations reflecting diverse risk factors, including tobacco, alcohol, and HPV infection. Oropharyngeal cancers attributed to HPV have significantly increased, particularly in regions like the United States. The HPV16 genome, characterized by oncoproteins E6 and E7, disrupts crucial cell cycle regulators, including tumor protein p53 (TP53) and retinoblastoma (Rb), contributing to HNSCC pathogenesis. P16 immunohistochemistry (IHC) is a reliable surrogate marker for HPV16 positivity, while in situ hybridization and polymerase chain reaction (PCR) techniques, notably reverse transcription-quantitative PCR (RT-qPCR), offer sensitive HPV detection. Liquid-based RT-qPCR, especially in saliva, shows promise for noninvasive HPV detection, offering simplicity, cost-effectiveness, and patient compliance. These molecular advancements enhance diagnostic accuracy, guide treatment decisions, and improve patient outcomes in HNC management. In conclusion, advances in HPV detection and molecular understanding have significant clinical management implications. Integrating these advancements into routine practice could ultimately improve patient outcomes.
Topics: Humans; Papillomavirus Infections; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Human papillomavirus 16; Papillomaviridae; Human papillomavirus 18; Human Papillomavirus Viruses
PubMed: 38884391
DOI: 10.1002/jmv.29746